1. |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33.
|
2. |
Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res, 2014, 3(4): 242-249.
|
3. |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26(21): 3552-3559.
|
4. |
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 2014, 383(9928): 1561-1571.
|
5. |
Nasser NJ, Gorenberg M, Agbarya A. First line immunotherapy for non-small cell lung cancer. Pharmaceuticals (Basel), 2020, 13(11): 373.
|
6. |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stageⅢnon-small-cell lung cancer. N Engl J Med, 2017, 377(20): 1919-1929.
|
7. |
Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun, 2021, 12(1): 6770.
|
8. |
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet, 2021, 398(10308): 1344-1357.
|
9. |
Wakelee H, Altorki N, Felip E, et al. PL03.09 IMpower010: Overall survival interim analysis of a phaseⅢ study of Atezolizumab vs. best supportive care in resected NSCLC. J Thorac Oncol, 2022, 17(9): S2.
|
10. |
O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol, 2022, 23(10): 1274-1286.
|
11. |
https://www.clinicaltrials.gov/.
|
12. |
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase Ⅲtrial after a median follow-up of 11 years. J Clin Oncol, 2012, 30(16): 1926-1933.
|
13. |
Zhang X, Wu T, Cai X, et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities. Front Immunol, 2022, 13: 795972.
|
14. |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
|
15. |
Wislez M, Mazieres J, Lavole A, et al. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): Results from a multicenter study (IFCT-1601 IONESCO). J Immunother Cancer, 2022, 10(10): e005636.
|
16. |
Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med, 2022, 386(21): 1973-1985.
|
17. |
Ford PM, Spicer J, Lu S, et al. Abstract CT003: Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs. chemo as neoadjuvant treatment (tx) for resectable (ⅠB-ⅢA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Res, 2021, 81 (13_Supplement): CT003.
|
18. |
Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med, 2021, 27(3): 504-514.
|
19. |
Spicer J, Cascone T, Kar G, et al. 929MO: Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study. Ann Oncol, 2022, 33(Suppl_7): S427-S437.
|
20. |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 2020, 21(11): 1413-1422.
|
21. |
Mariano PP, Ernest N, Jose LGL, et al. Nivolumab+chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage ⅢA NSCLC: Primary endpoint results of pathological complete response (pCR) from phaseⅡ NADIMⅡ trial. J Clin Oncol, 2020: 8501.
|
22. |
Romero A, Serna R, Nadal E, et al. MA06.03: Pre-treatment ctDNA levels significantly predicts of OS and PFS in NADIMⅡ trial. J Thorac Oncol, 2022, 17(9): S63.
|
23. |
Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stageⅢA(N2) non-small-cell lung cancer: A multicenter single-arm phaseⅡtrial. J Clin Oncol, 2021, 39(26): 2872-2880.
|
24. |
Zhao J, Zhao L, Guo W, et al. Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab and apatinib in patients with resectable NSCLC: A phase 2 clinical trial. J Thorac Oncol, 2023, 18(6): 780-791.
|
25. |
Cascone T, Awad MM, Spicer JD, et al. LBA1-CheckMate 77T: Phase Ⅲstudy comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs. neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage Ⅱ-Ⅲb NSCLC. Ann Oncol, 2023: S1254-S1335.
|
26. |
Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med, 2023, 389(18): 1672-1684.
|
27. |
Yue D, Wang W, Liu H, et al. LBA58 pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage Ⅱ-ⅢA NSCLC patients (pts) in the phase Ⅲ(Ph3) RATIONALE-315 trial. Ann Oncol, 2023, 34(Supplement 2): S1299.
|
28. |
Lu S, Wu L, Zhang W, et al. Perioperative toripalimab+platinum-doublet chemotherapy vs chemotherapy in resectable stage Ⅱ/Ⅲnon-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phaseⅢ Neotorch study. J Clin Oncol, 2023: 425126.
|
29. |
Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med, 2023, 389(6): 491-503.
|
30. |
Rhodin KE, Rucker AJ, Ready NE, et al. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons. J Thorac Cardiovasc Surg, 2020, 159(4): 1616-1623.
|
31. |
Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs. chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol, 2021, 39(15_suppl): 8503-e.
|
32. |
Zhang B, Xiao Q, Xiao H, et al. Perioperative outcomes of video-assisted thoracoscopic surgery versus open thoracotomy after neoadjuvant chemoimmunotherapy in resectable NSCLC. Front Oncol, 2022, 12: 858189.
|
33. |
Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO). Non-Small Cell Lung Cancer. Beijing: People's Medical Publishing House.
|
34. |
中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会. 肿瘤突变负荷应用于肺癌免疫治疗的专家共识. 中国肺癌杂志, 2021, 24(11): 743-752.
|
35. |
Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5. 2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2017, 15(4): 504-535.
|
36. |
Deng H, Zhao Y, Cai X, et al. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for early-stage non-small cell lung cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 2022, 170: 103582.
|
37. |
Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phaseⅡtrial. Nat Med, 2022, 28(10): 2155-2161.
|
38. |
吴一龙, 陆舜, 程颖, 等. 非小细胞肺癌分子残留病灶专家共识. 循证医学, 2021, 21(3): 129-135.
|
39. |
Xia L, Mei J, Kang R, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res, 2022, 28(15): 3308-3317.
|
40. |
Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med, 2023, 388(9): 813-823.
|
41. |
Chaft JE, Hellmann MD, Velez MJ, et al. Initial experience with lung cancer resection after treatment with t-cell checkpoint inhibitors. Ann Thorac Surg, 2017, 104(3): e217-e218.
|
42. |
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol, 2015, 33(31): 3541-3543.
|
43. |
Jia XH, Xu H, Geng LY, et al. Efficacy and safety of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A meta-analysis. Lung Cancer, 2020, 147: 143-153.
|
44. |
Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg, 2018, 106(1): 178-183.
|
45. |
Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
|
46. |
Ren S, Wang C, Shen J, et al. Neoadjuvant immunotherapy with resectable non-small cell lung cancer: Recent advances and future challenges. J Thorac Dis, 2020, 12(4): 1615-1620.
|